Wese munhu anoziva kuti kenza yemapapu, kenza yemudumbu, kenza yemudumbu, uye kenza yemazamu zviri nyore kuongorora kuburikidza nekuongororwa kwemuviri, saka varwere vegomarara vanoonekwa nekukurumidza vane fungidziro yakanaka uye nguva yavo yekupona inorebesa.
However, liver cancer, another serious life-threatening cancer that accounts for more than 55% of the world’s cancers in China, is difficult to be diagnosed early. Most patients are diagnosed late and lose the chance of surgery. Although other treatments are diverse, it is difficult to maintain long-term survival. The early diagnosis of gomarara rechiropa has always been a difficult problem in the tumor world.
Panguva ino, kubudirira kweChinese masayendisiti kunonyanya kukodzera kudada kwedu!
Musi wa12 Kurume, Proceedings of the American Academy of Sciences (PNAS) yakaburitsa iyo isina masero DNA (cfDNA) uye mapuroteni mamaki akapedzwa neNational Cancer Center, Chipatara cheCancer cheChinese Academy of Medical Science neBeijing Panshengzi Gene Technology Co. ., Ltd. Mhedzisiro yekutanga kuongororwa kwegomarara rechiropa mune vanotarisira boka revanotakura HBV.
Chidzidzo ichi chakashandisa iyo liquid biopsy nzira yecfDNA gene mutation yakasanganiswa nemaprotein marker yakazvimiririra yakagadziridzwa nemaChinese masayendisiti-HCCscreen. Mushure mekuongororwa kwakasimba kwekiriniki, mhedzisiro yekutsvagisa inotarisirwa kushandiswa kuongororwa kwekutanga kwegomarara rechiropa.
Muchidzidzo ichi, kenza yechiropa yekutanga isingasviki 3 cm inogona kuwanikwa. Vatsvagiri vakawana masampu eropa emusero-isina DNA shanduko uye mapuroteni mamaki, uye akaongorora 331 HBV vatakuri vane yakajairika alpha-fetoprotein uye B-ultrasound mhedzisiro.
Mhedzisiro 24 kesi dzakaonekwa (zvichida nekenza yechiropa), uye mukutevera 6 kusvika 8 mwedzi, 4 zviitiko zvakawanikwa zvine kenza yechiropa. Vakasara ve307 varwere vakanga vasina kunaka uye hapana kenza yechiropa yakawanikwa panguva yekutevera. Wana 100% senitivity, 94% chaiyo uye 17% yakanaka yekufungidzira kukosha.
Early-stage liver cancer can be detected by blood testing from asymptomatic HBV carriers. This technology can achieve accurate detection of common mutations in liver cancer such as cfDNA point mutations, insertion deletion mutations, and HBV virus integration. At present, the research method has been further optimized, the sensitivity is stable at more than 93%, and the specificity can be increased to more than 98%.
Nekudaro, parizvino, tekinoroji iyi ichiri mudanho rekutsvagisa, uye haisati yatenderwa zviri pamutemo kuongororwa kwekiriniki yekuongororwa kenza yechiropa. Zvakadaro, vanhu vane njodzi huru kana kuti vanoda kuvhenekwa gomarara nekukurumidza vanogona kusarudza kuenda kuchipatara chenguva dzose kana kunzvimbo yekurapa kunoongororwa nanachiremba kuti vavhenekwe gomarara rekare!
Parizvino, vanhu vazhinji muChina vanofarira kufamba uye kutenga muJapan. Nenzira, zadzisa kuongororwa kwekurapa kwakadzama, kusanganisira kuongororwa kwekutanga kwekenza dzakasiyana, uye zvipe runyararo rwepfungwa paunenge uchitamba, kuve nechokwadi chemuviri une hutano.
